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We report follow-up results from the randomized, placebo-controlled, phase 3 HELIOS trial of 56 
ibrutinib+bendamustine and rituximab (BR) for previously treated chronic lymphocytic leukemia 57 
(CLL)/small lymphocytic lymphoma (SLL) without deletion 17p. Overall, 578 patients were randomized 58 
1:1 to either ibrutinib (420 mg daily) or placebo, in combination with 6 cycles of BR, followed by 59 
ibrutinib or placebo alone. Median follow-up was 34.8 months (range: 0.1–45.8). Investigator-assessed 60 
median progression-free survival (PFS) was not reached for ibrutinib+BR, versus 14.3 months for 61 
placebo+BR (hazard ratio [HR] [95% CI], 0.206 [0.159–0.265]; P<0.0001); 36-month PFS rates were 68.0% 62 
versus 13.9%, respectively. The results are consistent with the primary analysis findings (HR=0.203, as 63 
assessed by independent review committee, with 17-month median follow-up). Median overall survival 64 
was not reached in either arm; HR (95% CI) for ibrutinib+BR versus placebo: 0.652 (0.454–0.935; 65 
P=0.019). Minimal residual disease (MRD)-negative response rates were 26.3% for ibrutinib+BR and 66 
6.2% for placebo+BR (P<0.0001). Incidence of treatment-emergent adverse events (including grade 3–4) 67 
were generally consistent with the initial HELIOS report. These long-term data support improved survival 68 
outcomes and deepening responses with ibrutinib+BR compared with BR in relapsed CLL/SLL. 69 
 70 




  75 




Ibrutinib is an oral, once-daily inhibitor of Bruton’s tyrosine kinase, an essential enzyme in the B-cell 77 
receptor signaling pathway [1-3]. The efficacy and safety of ibrutinib has been demonstrated in patients 78 
with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in treatment-naïve and 79 
relapsed/refractory settings [4,5], leading to approvals for these indications [6,7]. Ibrutinib as a single-80 
agent for previously treated patients with CLL/SLL was evaluated in a phase 1b/2 study (Study 1102 and 81 
its extension, Study 1103) and the phase 3 RESONATE study of ibrutinib versus ofatumumab [8,9]. Long-82 
term follow-up data from these studies showed that continuing ibrutinib treatment leads to durable and 83 
deepening responses. The phase 1b/2 study (101 patients with previously treated CLL) reported an 84 
overall response rate (ORR) of 89% with 10% complete responses (CRs) and a median progression-free 85 
survival (PFS) of 52 months after 5-year follow-up, while the median overall survival (OS) remained 86 
unreached [9]. In the RESONATE™ study (195 previously treated CLL patients), the ORR was 91% (with 87 
9% CR/CRi [CR with incomplete bone marrow recovery]) at a median follow-up of 44 months versus 83% 88 
(2% CR/CRi) after median follow-up of 9.4 months [8]. 89 
Chemoimmunotherapy regimens such bendamustine and rituximab (BR) or fludarabine, 90 
cyclophosphamide and rituximab (FCR) are efficacious in patients with relapsed/refractory CLL, but their 91 
use is often limited by patient tolerability [10]. BR has been commonly used [11], largely based on a 92 
phase 2 study in relapsed/refractory CLL that showed an ORR of 59%, with 9% of patients achieving a CR, 93 
and a median PFS and OS of 15 and 34 months, respectively [12]. The BR regimen formed the backbone 94 
of the phase 1b study that led to the development of the HELIOS study [13]. In this phase 1b study 95 
(Study 1108) with 30 previously treated patients receiving up to six cycles of BR+continuous ibrutinib, 96 
the CR rate was 17% after a median of 15.8 months of follow-up, increasing to 40% at a median follow-97 
up of 37.3 months [13]. 98 
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In the phase 3 HELIOS trial of 578 patients with relapsed/refractory CLL, ibrutinib+BR (≤6 cycles) 99 
significantly improved PFS at the initial analysis (median follow-up 17 months); median PFS was not 100 
reached in the ibrutinib arm versus 13.3 months in the placebo arm (hazard ratio [HR]=0.203, 95% CI: 101 
0.150–0.276; P<0.0001) [14]. The findings of HELIOS supported the approval of ibrutinib+BR in the US 102 
and EU for patients with relapsed/refractory CLL/SLL [6,7]. 103 
For traditional chemoimmunotherapy, minimal residual disease (MRD)-negative responses are 104 
prognostic for prolonged PFS [15] and may be a more potent predictor of PFS than the clinical response 105 
assessment according to International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines 106 
[16]. Because of limited long-term follow-up data on novel targeted therapies, it is unclear if MRD-107 
negative remissions are similarly prognostic in patients receiving these agents [17]. Evaluation of MRD 108 
status is of particular interest in ibrutinib-containing regimens, as MRD negativity represents a lower 109 
disease burden and is being investigated as a marker for treatment discontinuation with novel agents, 110 
which are usually administered until progression or unacceptable toxicity. HELIOS was the first study to 111 
evaluate MRD status in ibrutinib-treated patients. At 17-month median follow-up, the proportion of 112 
patients that achieved MRD negativity was higher with ibrutinib+BR versus placebo+BR (13% vs 5%; 113 
P=0.0011) [14]. 114 
As ibrutinib is a continuously administered oral once-daily therapy, data addressing the safety profile of 115 
ibrutinib over time, longer-term outcomes, and efficacy in patient subgroups become increasingly 116 
relevant. We report updated data from HELIOS (3-year follow-up) to determine survival outcomes, 117 
evolution of responses and durability of remissions across patient subgroups, as well as long-term 118 
safety. 119 
 120 
Subjects and Methods 121 
Study design and patients 122 
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Study design and participants have been previously described [14]. Briefly, HELIOS (Clinicaltrials.gov 123 
#NCT01611090) is a phase 3, randomized, placebo-controlled, double-blind study of 578 patients 124 
conducted at 133 sites in 21 countries between September 19, 2012, and January 21, 2014. Eligible 125 
patients were aged ≥18 years, had a diagnosis of CLL/SLL according iwCLL criteria [18], 126 
relapsed/refractory disease following ≥1 previous lines of systemic therapy, an Eastern Cooperative 127 
Oncology Group performance status of 0–1, measurable lymph node disease (>1.5 cm) by computed 128 
tomography (CT) scan and adequate liver and kidney function. Patients with deletion 17p (≥20% of 129 
blood or bone marrow cells examined by fluorescence in situ hybridization) were excluded due to 130 
known poor response to BR. 131 
Patients were randomly assigned 1:1 to ibrutinib (420 mg daily)+BR or placebo+BR. BR was administered 132 
for up to six cycles (bendamustine: 70 mg/m² intravenously on days 2–3 in cycle 1 and days 1–2 in cycles 133 
2–6; rituximab: 375 mg/m² on day 1 of cycle 1 and 500 mg/m² on day 1 of cycles 2–6). After 6 months of 134 
BR with ibrutinib or placebo therapy, patients continued ibrutinib treatment or placebo alone until 135 
disease progression or unacceptable toxicity. Following the pre-specified interim analysis, the study was 136 
unblinded and placebo treatment was discontinued. Subsequently, adverse events (AEs) were collected 137 
only for patients continuing on ibrutinib, although patients originally treated with placebo were 138 
followed with regular disease evaluations and were able to crossover to ibrutinib at the time of 139 
progression and meeting iwCLL criteria for treatment. 140 
 141 
Endpoints and assessments 142 
The primary endpoint was Independent Review Committee (IRC)-assessed PFS, for which results were 143 
reported previously [14]. Investigator-assessed endpoints were used for the follow-up analyses reported 144 
here. Key secondary endpoints were investigator-assessed PFS, OS and response rates, proportion of 145 
patients with MRD-negative responses (<1 CLL cell per 10 000 leukocytes or <0.01%) confirmed by 146 
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central laboratory assessment of peripheral blood or bone marrow aspirate, and safety. PFS2 (time 147 
interval from randomization to disease progression on next-line treatment or death, or start of next 148 
antineoplastic therapy if no progressive disease [PD] was recorded) was also assessed. 149 
Assessment of tumor response was conducted in accordance with iwCLL 2008 criteria [18]. Prior to the 150 
interim analysis, CT scans were performed at baseline, then every 12 weeks for 2 years and every 6 151 
months thereafter. Following the interim analysis, disease evaluations based on the discretion of 152 
investigators continued every 3 months in both arms; for patients randomized into the ibrutinib arm 153 
who had not yet progressed, CT scans continued every 6 months until progression. Analysis of MRD was 154 
initially performed on bone marrow sampled at the time of radiological documentation of CR, with 155 
subsequent analyses of peripheral blood every 12 weeks. After the interim analysis, the protocol was 156 
amended to include MRD analysis for all patients with a partial response (PR) or better. Testing was 157 
performed at a central laboratory by flow cytometry using an eight-color panel of antibodies in keeping 158 
with the EuroFlow panel [19]. 159 
 160 
Statistical analysis 161 
Statistical analyses have been described previously [14]. Approximately 580 patients were randomized 162 
to observe 342 PFS events, to detect an HR of 0.7 for the ibrutinib+BR group relative to the placebo+BR 163 
group with 90% power at a one-sided significance level of 0.025, using a group sequential testing design. 164 
The distribution of time-to-event endpoints was estimated using the Kaplan-Meier method. 165 
The analysis of PFS and OS using the long-term follow-up data was similar to those used for the primary 166 
analyses, except that investigator assessments were used for follow-up data. For patients in the 167 
placebo+BR group who crossed over to receive ibrutinib, no adjustment was made for OS analysis, i.e., 168 
the OS is defined as the time interval from randomization to death irrespective of cause. For surviving 169 
patients, the OS is censored at the last date known to be alive. Separate analyses of OS corrected for 170 
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crossover were performed using the Inverse Probability of Censoring Weighting and the Rank Preserving 171 
Structural Failure Time Methods (Supplementary Figure S1). The MRD-negative response rate was 172 
compared between treatment arms using the Fisher’s exact test; MRD assessments continued until 173 
crossover for the placebo+BR arm. 174 
 175 
RESULTS 176 
Study population 177 
The data represent outcomes of 6 months of combination therapy (ibrutinib+BR or placebo+BR) 178 
followed by over 2 years of continuous ibrutinib or placebo treatment. For consistency with the initial 179 
analysis, the treatment arms are referred to as ibrutinib+BR and placebo+BR. The median follow-up 180 
period at this analysis was 34.8 months (range: 0.1–45.8), with a median treatment duration of 34.7 181 
months (range: 0.2–43.3) for ibrutinib+BR and 14.3 months (range: 0.2–30.6) months for placebo+BR 182 
(Supplementary Table S1). Sixty-six percent (188/287) of ibrutinib-treated patients remained on 183 
treatment for ≥24 months. 184 
Patient disposition is shown in Table 1. A total of 160 (55.4%) patients who had confirmed PD in the 185 
placebo+BR arm crossed over to ibrutinib. At the time of this analysis, patients received crossover 186 
therapy for a median of 16.9 months (range: 0.2–26.3). Patient demographics and baseline 187 
characteristics data were previously reported and were balanced between arms (Supplementary table 188 
S2) [14]. 189 
 190 
Efficacy 191 
Investigator-assessed PFS was significantly longer with ibrutinib+BR (not reached vs 14.3 months for 192 
placebo+BR [HR (95% CI), 0.206 (0.159–0.265); P<0.0001]) (Figure 1a), and the 36-month PFS rate was 193 
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68.0% versus 13.9%, respectively. Median OS was not reached in either arm, but was significantly longer 194 
for the ibrutinib+BR arm (HR [95% CI], 0.652 [0.454–0.935]; P=0.019) (Figure 1b); the 36-month OS rate 195 
for each arm was 81.6% versus 72.9%, respectively. An analysis of OS that corrected for crossover from 196 
the placebo+BR arm to ibrutinib+BR confirmed the OS advantage of ibrutinib+BR (Supplementary Figure 197 
S1). 198 
In assessed subgroups, including bulky disease, chromosomal deletions, ZAP70 elevation and 199 
immunoglobulin heavy-chain variable region (IGHV) mutation status, PFS outcomes favored ibrutinib+BR 200 
over placebo+BR (Figure 2a, Supplementary Figure S3). PFS at 36 months was significantly longer in 201 
ibrutinib-treated patients, whether they had one or multiple lines of therapy (Figure 2b). For patients 202 
who had one prior therapy, 36-month PFS was 70.2% in the ibrutinib+BR arm (95% CI: 61.3–77.5) and 203 
15.5% in the placebo+BR arm (95% CI: 8.3–24.7; P<0.0001); for patients who had two or more prior 204 
therapies, 36-month PFS was 65.9% for ibrutinib+BR (95% CI: 56.8–73.5) and 11.2% with placebo+BR 205 
(95% CI: 6.5–17.4; P<0.0001). 206 
Median PFS2 was not reached in either arm but was significantly longer for patients assigned to 207 
ibrutinib+BR versus placebo+BR (HR [95% CI], 0.627 [0.445–0.881]; P=0.0067) (Supplementary Figure 208 
S2). Among 27 patients who discontinued ibrutinib+BR due to disease progression, 10 patients died 209 
(seven patients died due to PD, two due to AEs [pneumonia and cardiac arrest] and one of unknown 210 
causes following administration of subsequent CLL therapy). Eight patients received subsequent 211 
systemic CLL therapies, four in combination with rituximab. 212 
The investigator-assessed ORR was 87.2% for ibrutinib+BR and 66.4% for placebo+BR (P<0.0001). CR/CRi 213 
rates were 38.1% versus 8.0% (Figure 3a), which showed continued improvement over time versus the 214 
investigator-assessed CR/CRi rates of 21.4% and 5.9%, respectively, in the initial analysis [14]. Overall, 215 
211 patients in the ibrutinib+BR arm and 76 patients in the placebo+BR arm were evaluated for MRD; 216 
MRD-negative response rates in peripheral blood or bone marrow combined for the intent-to-treat 217 
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population were 26.3% (76/289) for ibrutinib+BR and 6.2% (18/289) for placebo+BR (P<0.0001) (Figure 218 
3b). The majority of patients (67.1%) in the ibrutinib+BR arm who achieved MRD negativity had a CR/CRi 219 
as their best response; 32.9% patients had a PR as their best response. Of these MRD-negative patients 220 
in the ibrutinib+BR arm with PR as their best response, the CR criteria not met are listed in 221 
Supplementary Table S3. In the placebo+BR arm, 8/18 MRD-negative patients (44.4%) had PR as their 222 
best response. Patients who did not achieve CR/PR or who progressed prior to MRD testing being 223 
implemented for all responding patients had a shorter PFS (Figure 4a–b). Among MRD-evaluated 224 
patients, ibrutinib+BR showed a more sustained PFS over placebo+BR at each level of MRD (MRD-225 
negative status <0.01%, HR [95% CI], 0.121 [0.036–0.408], P<0.0001; MRD ≥0.01% to <1%, HR [95%CI], 226 
0.153 [0.063–0.374], P<0.0001; or MRD ≥1 to <10%, HR [95%CI], 0.110 [0.035–0.348], P<0.0001) (Figure 227 
4a–b). In patients receiving ibrutinib+BR, the 36-month PFS rate for MRD-negative patients was 88.6% 228 
(95% CI: 76.8–94.6); for those with residual disease (MRD ≥0.01%), it was 60.1% (95% CI: 52.6–66.8). In 229 
the placebo+BR arm, the 36-month PFS rate in MRD-negative patients was 54.5% (95% CI: 29.2–74.2) 230 
and 11.2% (95% CI: 7.1–16.3) for patients with residual disease. A multivariate analysis revealed no 231 
difference in OS according to MRD status in responding patients. 232 
 233 
Safety 234 
Following the interim analysis, patients who were randomized to placebo+BR stopped treatment and 235 
either crossed over to receive next-line treatment with ibrutinib or remained in follow-up until 236 
progression. Per protocol, safety data were collected for 30 days after the last dose of study medication 237 
(placebo or BR). Therefore, only safety data for patients randomized to ibrutinib+BR are presented 238 
(Table 2); comparison between the two treatment arms up to the interim analysis has previously been 239 
published [14]. Treatment-emergent AEs (TEAEs) observed in over 10% of patients, and their prevalence 240 
over time, are listed in Table 3. The prevalence of TEAEs decreased over time after year 1, except for 241 
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muscle spasms and hypertension, which remained stable (Table 3).The proportion of patients with all-242 
grade AEs in the ibrutinib+BR arm was 98.3%, with 78.7% of patients reporting grade 3 or 4 events. 243 
Grade ≥3 AEs reported in ≥2% of patients are presented in Supplementary Table S4; the most common 244 
grade ≥3 AEs were neutropenia (53.7%), thrombocytopenia (15.0%), pneumonia (14.3%) and febrile 245 
neutropenia (12.5%), consistent with the initial analysis [14]. Serious TEAEs (i.e., life-threatening, 246 
requiring hospitalization or resulting in persistent/significant incapacity) occurred in 176 (61.3%) 247 
patients in the ibrutinib+BR arm; the most common were pneumonia (13.6%) and febrile neutropenia 248 
(10.1%). Serious atrial fibrillation (AF) or flutter was reported for 4.9% of patients (compared with 2.8% 249 
reporting AF in the initial analysis) [14]. There were 28 (9.8%) TEAEs leading to death in the ibrutinib+BR 250 
arm (compared with 19 [6.6%] reported in the initial analysis) [14], of which the most frequent were 251 
infections; a complete list of causes are included in Supplementary Table S5. 252 
Overall, the incidence of AEs of interest, including cytopenias, bleeding and infections, reduced during 253 
the course of the follow-up period (Table 4). Most AEs occurred within the first 12 months, with a sharp 254 
decrease in onset of new events after 12 months. Bleeding events (all grades) were reported in 34.5% of 255 
patients in the ibrutinib+BR arm (Table 4) versus 31% of patients in the initial report [14]; most were 256 
grade 1/2 events. No new major hemorrhage events or deaths due to bleeding or major hemorrhage 257 
events were reported during extended follow-up. 258 
Ibrutinib therapy is generally well tolerated, but has been associated with AF. A detailed review of AF 259 
following ibrutinib treatment in HELIOS and other randomized clinical trials investigating ibrutinib has 260 
been recently published [20]. During extended follow-up, eight additional patients in the ibrutinib+BR 261 
arm developed AF/flutter, for a total of 29 patients (10.1%). The majority of AF events (17/29) during 262 
the entire study duration in the ibrutinib+BR arm were grade 1/2. While dose interruption was normal in 263 
these cases, none required dose reductions and none were fatal; four (1.4%) led to treatment 264 
discontinuation. 265 
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Patients randomized to placebo+BR who crossed over to the ibrutinib+BR arm did not demonstrate any 266 
difference in type or incidence of AEs compared with patients originally randomized to ibrutinib+BR 267 
(Supplementary Table S6). 268 
 269 
DISCUSSION 270 
The HELIOS study was conducted in patients with relapsed/refractory CLL/SLL and is the first trial to 271 
show a survival benefit with ibrutinib-based therapy versus a standard chemoimmunotherapy regimen, 272 
even in the context of a crossover design. These results support the continued use of ibrutinib, with 273 
maintenance of superior PFS and OS versus the placebo+BR arm and an increase in ORR and CR rates 274 
over time. It is notable that longer-term follow-up revealed a significant improvement in survival for 275 
ibrutinib+BR-treated patients compared with placebo+BR, despite the possibility of crossover after 276 
progression. Additionally, deeper responses were reported with continuous ibrutinib therapy, with rates 277 
of investigator-assessed CR/CRi and MRD-negative response rising to 38% and 26%, respectively 278 
(compared with IRC-assessed rates of 21% and 13% at the primary analysis) [14]. This finding is 279 
consistent with the phase 1b study 1108 of ibrutinib+BR, in which CR rates increased from 17% to 40% 280 
with 15.7 to 35.4 months of follow-up, respectively [13]. 281 
Among those tested for MRD, patients in the ibrutinib+BR arm demonstrated prolonged PFS compared 282 
with those in the placebo+BR armat the same MRD level. Caution is warranted in interpreting the MRD 283 
analyses due to the relatively small numbers of MRD-tested patients in the placebo+BR arm and the 284 
potential that longer-term follow-up will be required to fully understand the prognostic significance of 285 
specific MRD levels in ibrutinib+BR-treated patients. 286 
The evolution of ORR and of CR rates following ibrutinib monotherapy in study 1102 for treatment-naïve 287 
(ORR, 71% to 84%, CR 13% to 23%, at 22 months to 3 years of follow-up) or previously treated (ORR, 288 
71% to 90%, CR 2% to 7% from 26 months to 3 years of follow-up) CLL/SLL patients demonstrates that 289 
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ibrutinib is associated with durable and deep responses as treatment continues [21]. The results from 290 
the HELIOS study have further shown that in patients with relapsed/refractory disease, an induction-291 
type period of ibrutinib+BR therapy followed by continued ibrutinib treatment produces better 292 
responses than BR therapy alone and improves outcomes as the duration of therapy increases [14]. The 293 
extended follow-up further confirmed that the positive effects on PFS of continuing ibrutinib following 294 
ibrutinib+BR are maintained irrespective of the number of prior lines of therapy or the presence of poor 295 
prognostic factors.  296 
It remains unclear whether ibrutinib+BR provides benefits beyond those observed with ibrutinib 297 
monotherapy. In the RESONATE trial, which investigated ibrutinib monotherapy in patients with CLL, the 298 
3-year PFS and OS rates for ibrutinib were 59% and 74%, respectively. In our study, 3-year PFS and OS 299 
rates for the ibrutinib+BR arm were 68% and 82%, respectively.  However, cross-trial comparisons are 300 
notoriously difficult to interpret and firm conclusions generally impossible to reach due to potential 301 
differences in study designs and treatment populations (e.g., HELIOS did not enroll patients with 302 
deletion 17p); an indirect treatment comparison of the HELIOS and RESONATE trials (ibrutinib+BR vs 303 
ibrutinib arms respectively) following adjustment for known confounders has recently been published 304 
[22].  At a median follow-up of 17 and 19 months, respectively, there was no difference in median PFS or 305 
OS, suggesting that addition of BR to ibrutinib does not improve outcomes compared with single-agent 306 
ibrutinib. An ongoing study directly comparing BR, ibrutinib+rituximab and ibrutinib alone in treatment-307 
naïve CLL patients (clinicaltrials.gov NCT01886872) will provide more insights into the relative efficacy of 308 
chemoimmunotherapy versus ibrutinib alone or with rituximab. 309 
Importantly, the extended follow-up data supported the manageable safety profile of ibrutinib, allowing 310 
for continued dosing following the initial induction with BR. The pattern and incidence of AEs and TEAEs 311 
was similar to the initial analysis when treatment extended beyond 17 months [14], and was 312 
comparable with the safety profile reported in other clinical trials of ibrutinib in CLL patients 313 
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[5,14,21,23]. Eight additional patients in the ibrutinib+BR arm reported AF/flutter during follow-up, 314 
consistent with reviews and meta-analyses documenting an increased risk of developing AF in ibrutinib-315 
treated patients versus comparator treatments [20,24] and an elevated risk over time [20]. It has 316 
previously been reported that 5–9% of CLL/SLL patients receiving ibrutinib are affected [25]. The 317 
incidence of bleeding events increased slightly with continued follow-up in the ibrutinib+BR arm; 318 
however, there were no new major hemorrhagic events or bleeding-related deaths. These long-term 319 
follow-up data support improved survival outcomes with ibrutinib+BR compared with BR alone in 320 
relapsed CLL/SLL. In addition, continued ibrutinib monotherapy following the end of 321 
chemoimmunotherapy results in continuing improvement in the depth of remission. 322 
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Figure Legends 431 
Figure 1. Three-year follow-up of investigator-assessed (a) progression-free survival and (b) overall 432 
survival. 433 
BR, bendamustine and rituximab; CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, 434 
progression-free survival. 435 
Figure 2. Investigator-assessed PFS by (a) prognostic factors and (b) prior lines of therapy. 436 
BR, bendamustine and rituximab; CI, confidence interval; EVT, event; IGHV, immunoglobulin heavy-chain 437 
variable; HR, hazard ratio; LDi, longest diameter; NE, not evaluable; PFS, progression-free survival. 438 
Figure 3. Cumulative response rates over time (investigator-assessed) for (a) complete response and (b) 439 
MRD status. Note: The term “induction therapy” refers to BR. The induction phase is defined as the first 440 
six cycles of the study, when BR is given along with study drug (ibrutinib or placebo) as combination 441 
therapy. The end of the induction phase is the last dose of B or R + 30 days. 442 
BR, bendamustine and rituximab; CR, complete response; CRi, CR with incomplete bone marrow 443 
recovery; MRD, minimal residual disease. 444 
Note: Percentages are based on number of patients in the intent-to-treat analysis set in each treatment 445 
arm.  446 
Figure 4. Investigator-assessed PFS by MRD level for (a) ibrutinib+BR and (b) placebo + BR arms. 447 
BR, bendamustine and rituximab; MRD, minimal residual disease; PFS, progression-free survival. 448 
